Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update
Company Announcements

Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update

Moleculin Biotech ( (MBRX) ) has provided an update.

Moleculin Biotech, Inc. is set to host an engaging Virtual Acute Myeloid Leukemia KOL event on October 14, 2024, which will feature discussions with top medical experts on the potential of Annamycin to revolutionize AML treatment. The company also highlights their pivotal Phase 3 MIRACLE trial aimed at accelerated approval of Annamycin in combination with cytarabine for patients with relapsed or refractory AML. Investors and interested parties can join the event via webcast to gain insights into Moleculin’s advanced pipeline targeting challenging tumors and viruses.

See more insights into MBRX stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMoleculin Biotech Gains IRB Approval for Phase 3 Trial
TipRanks Auto-Generated NewsdeskMoleculin Biotech Unveils New Corporate Presentation
TheFlyMoleculin Biotech’s Phase 3 trial of Annamycin approved by Review Board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App